Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
Abbott has previously opposed legislation to test strips, but noted an 89% increase in fentanyl deaths in Texas over the past year.
Read Full NewsMerck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.
New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.
New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.
5 FDA Headlines You Missed in November 2025
1.
Trial Questions Role of Dual Immunotherapy in First-Line NSCLC
2.
Transplantation Fails to Improve Survival in Mantle Cell Lymphoma
3.
In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.
4.
PSMA PET Beats MRI in Prostate Cancer Staging Study
5.
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor
1.
Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence
2.
Multiple Primary Lung Cancer: Multidisciplinary Advances in Diagnosis and Care
3.
Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment
4.
Advancements in Breast Cancer Treatment: From Chemotherapy to Immunotherapy
5.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Navigating the Complexities of Ph Negative ALL - Part VIII
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge